Linc

Linc EPS Growth

The EPS Growth of Linc (LINC.ST) as of Nov 20, 2026 is -130.70 %. In the previous year, EPS Growth was 110.12 % — a change of -218.69% (lower).

EPS Growth

-130.70 %

YoY

-218.69%

Last updated:

EPS Growth of Linc is 2025 -130.70 % . EPS Growth of Linc was 2024 110.12 % . It decreases by -218.69% lower compared to the previous year.

The Linc EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2019
88.71 SEK
Jan 1, 2020
31.35 SEK
Jan 1, 2021
-104.39 SEK
Jan 1, 2022
-1,995.66 SEK
Jan 1, 2023
185.64 SEK
Jan 1, 2024
110.12 SEK
Jan 1, 2025
-130.70 SEK
The Linc EPS Growth history
YEAREPS GrowthYoY
-130.70 %-218.69%
110.12 %-40.68%
185.64 %-109.30%
-1,995.66 %+1,811.65%
-104.39 %-433.01%
31.35 %-64.66%
88.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

EPS Growth of Linc is -130.70 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Linc since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Linc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Linc

All Key Metrics — Linc